Pearl Steinzor

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment, according to one study.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

Changing High-Risk Asthma in Memphis through Partnerships significantly decreased health care use related to asthma among children.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Coverage from the Institute for Value-Based Medicine event in Tampa, Florida, with Moffitt Cancer Center.

Coverage in the February 2024 issue of Evidence-Based Oncology.

Children treated with dupilumab showed improved lung function compared with placebo group, according to one study.

Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, discusses methods for identifying patients with indolent systemic mastocyctosis (ISM) using health claims data.

It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.

Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.

Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis.

These modifiable environmental factors were independently associated with asthma severity, according to one study.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.

A Mendelian randomization analysis supported an increasing causal relationship between asthma and lung cancer risk, particularly in smokers and lung squamous cell carcinoma.

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the complex landscape of proposed health care rules, and the potential impact of CMS' Advancing Interoperability and Prior Authorizations Rule.

Mike Brown, vice president of managed services at Cardinal Health, discusses Cardinal Health's goals to to leverage technology, while reducing costs to the health care system.

This association remained significant even after controlling for cigarette use and demographic characteristics.

Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, suggests that some patients with indolent systemic mastocytosis (ISM) may be progressing at a faster rate than expected, and will need to be monitored and started on appropriate therapies.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the historic progression of health information technology and the role interoperability plays in secure exchanging of patient data.

Mike Brown, vice president of managed services at Cardinal Health, discusses how remote pharmacy services are revolutionizing patient care by improving accessibility and medication safety.

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.

Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.

A recent cohort study finds that prenatal opioid exposure is associated with increased risk of certain immune-related conditions, including asthma.

People of color with scalp psoriasis experienced significant improvement in scalp itch and patient-reported health-related quality-of-life outcomes.

David Adamson, MD, emphasizes the need for continuous education and building relationships with colleagues to navigate the complexities of reproductive rights and evolving care standards.